Pulse Biosciences Announces Podium Presentation of Nano-Pulse Stimulation™ Technology at Major Aesthetic Procedures Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Aug. 6, 2019-- Pulse Biosciences, Inc. (NASDAQ:PLSE), a bioelectric medicine technology company bringing to market its proprietary CellFX™ System, today announced its patented Nano-Pulse Stimulation™ (NPS™) technology will be featured in a series of podium presentations in the “Hot Topics” session of Controversies and Conversationsin Lasers & Cosmetic Surgery. This prestigious annual scientific symposium assembles the best and brightest specialists and innovators in the field of aesthetic procedures and features the most important advancements in the use of energy-based devices for dermatology. The event takes place on August 9–11, 2019, in San Francisco, Calif.

“We are honored that our groundbreaking Nano-Pulse Stimulation technology which powers our CellFX System was selected for a “Hot Topics” session during the first day of the upcoming Controversies meeting of specialists in new technologies,” said Darrin Uecker, President and CEO of Pulse Biosciences. “It is an acknowledgment to the clinical investigators and scientific advisors whose ongoing contributions continue to advance our CellFX System for use in dermatology.”

The non-thermal mechanism of action harnessed by the CellFX System is being investigated for a broad range of dermatologic applications. Pulse Biosciences looks forward to the presentation of its recent data during this important international forum, which adds to the expanding professional acceptance of our CellFX System with its innovative NPS technology and differentiated mechanism of action.

Session Presentations

“Hot Topics: Nano-Pulse Stimulation Technology” (Friday, August 9, 11:30 am Pacific Time). Presenters:

  • Dr. Thomas Rohrer, Mohs skin cancer and dermatologic surgeon in private practice at SkinCare Physicians in Boston, MA and Clinical Associate Professor of Dermatology at Brown University School of Medicine in Providence, RI. Dr. Rohrer will provide an overview of the many applications of NPS technology and will feature his own experience in its use treating Seborrheic Keratosis.
  • Dr. Girish Munavalli, Assistant Clinical Professor of Dermatology at Wake Forest University School of Medicine, Wake Forest, NC, and founding Medical Director of Dermatology, Laser and Vein Specialists of the Carolinas, Charlotte, NC. Dr. Munavalli will present results on the use of NPS technology for the treatment of Sebaceous Hyperplasia lesions and Warts.
  • Dr. Brian Zelickson, Associate Professor at the University of Minnesota Medical School and founding Medical Director of Zel Skin and Laser Specialists in Edina, MN. Dr. Zelickson will discuss early research into the potential for NPS technology to treat tattoo ink and will provide an update on key findings from the Basal Cell Carcinoma feasibility study, for which he was one of five principal investigators.

About Pulse Biosciences

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that improves and potentially extends the lives of patients. Our CellFX System is the first planned commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology to treat a variety of applications for which an optimal solution remains unfulfilled. NPS technology delivers nano-second pulses of high amplitude electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue. The cell-specific effects of NPS technology have been validated in a series of completed and ongoing clinical studies. In addition, early pre-clinical evidence suggests that NPS technology holds a promising future in immuno-oncology by demonstrating an ability to induce immunogenic cell death. We are preparing to commercially introduce our CellFX System during 2019 as a multi-application platform designed to address a broad range of dermatologic conditions. As part of the customer experience, the Company is offering a utilization-based revenue model and easy-access customer portal offering a suite of services. Our CellFX procedures offer customer value across an expanding spectrum of clinical applications. The initial commercial use will be in the clearance of common skin lesions, including sebaceous hyperplasia (SH) and seborrheic keratosis (SK) – two prevalent and difficult-to-treat benign skin conditions that share high demand among patients and practitioners for improved and durable aesthetic outcomes that lead to greater overall satisfaction. For more information about Pulse Biosciences and our CellFX System, please visit us at

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to or implying Pulse Biosciences’ expectations regarding commercialization of the CellFX system, regulatory clearance and the timing of FDA filings or approvals for products and indications, matters related to its pipeline of product candidates, future financial performance and business strategies and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

CAUTION: Pulse Biosciences’ CellFX System and Nano-Pulse Stimulation (NPS) are for investigational use only.

Source: Pulse Biosciences, Inc.

Brian Dow
Sr. Vice President and Chief Financial Officer

Gitanjali Jain Ogawa
Solebury Trout

Nadine D. Tosk
Nadine Tosk Communications